Synlogic (NASDAQ:SYBX – Get Free Report) and Kyntra Bio (NASDAQ:KYNB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.
Earnings and Valuation
This table compares Synlogic and Kyntra Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Synlogic | $8,000.00 | 1,822.04 | -$23.36 million | ($0.06) | -19.83 |
| Kyntra Bio | $6.44 million | 4.45 | $183.45 million | $45.30 | 0.16 |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Synlogic and Kyntra Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Synlogic | 1 | 0 | 0 | 0 | 1.00 |
| Kyntra Bio | 1 | 1 | 3 | 1 | 2.67 |
Kyntra Bio has a consensus target price of $37.25, suggesting a potential upside of 426.87%. Given Kyntra Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Synlogic.
Insider and Institutional Ownership
63.4% of Synlogic shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 2.6% of Synlogic shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Synlogic has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
Profitability
This table compares Synlogic and Kyntra Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Synlogic | N/A | -26.47% | -18.00% |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
Summary
Kyntra Bio beats Synlogic on 13 of the 15 factors compared between the two stocks.
About Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
